Ceftriaxone (Hospira) is a medicine containing the active ingredient(s) ceftriaxone. On this page you will find out more about Ceftriaxone (Hospira), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: ceftriaxone
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Ceftriaxone (Hospira) 1 g powder for injection, 1 vial
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Hospira Ceftriaxone Sodium for Injection is indicated for the treatment of the following infections when caused by susceptible aerobic organisms. Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Streptococcus species (excluding enterococci), methicillin sensitive Staphylococcus aureus, Haemophilus influenzae, H. parainfluenzae, Klebsiella species (including K. pneumoniae), E. coli, Enterobacter aerogenes, Proteus mirabilis and Serratia marcescens. Skin and Skin Structure Infections caused by methicillin sensitive Staphylococcus aureus, methicillin sensitive Staphylococcus epidermidis, Streptococcus Group B, Streptococcus Group G, Streptococcus pyogenes, Streptococcus viridans, Streptococcus species (excluding enterococci), Peptostreptococcus species, E. coli, Enterobacter cloacae, Klebsiella species (including K. pneumoniae, K. oxytoca), Proteus mirabilis, Morganella morganii, Serratia marcescens. Urinary Tract Infections (complicated and uncomplicated) caused by E. coli, Proteus mirabilis, Proteus vulgaris, M. morganii and Klebsiella species (including K. pneumoniae). Uncomplicated Gonorrhoea (cervical/urethral and rectal) caused by Neisseria gonorrhoea, including both penicillinase and non penicillinase producing strains. Bacterial Septicaemia caused by Streptococcus pneumoniae, E. coli and H. influenzae. Bone infections caused by methicillin sensitive S. aureus, methicillin sensitive S. epidermidis, streptococcus Group B, Streptococcus pneumoniae, Streptococcus species (excluding enterococci), E. coli, Enterobacter species, P. mirabilis and K. pneumoniae. Joint Infections caused by methicillin sensitive S. aureus, Streptococcus pneumoniae, Streptococcus species (excluding enterococci), E. coli, P. mirabilis, K. pneumoniae and Enterobacter species. Meningitis: The initial treatment, as a single agent, of meningitis in children and immunocompetent adults when presumed or proven to be caused by Haemophilus influenzae type b, Neisseria meningitidis, Streptococcus pneumoniae or Enterobacteriaceae pending culture and sensitivity results. Surgical Prophylaxis: The preoperative administration of a single 1g dose of ceftriaxone may reduce the incidence of post-operative infections in patients undergoing vaginal or abdominal hysterectomy or cholecystectomy in high risk patients, surgical procedures which are classified as contaminated or potentially contaminated and patients undergoing coronary artery bypass surgery. Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo controlled trials have been conducted. Susceptibility Testing: Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing.
Table of characteristics
|Visual appearance||Almost white or yellowish powder|
|Dosage Form||Injection, powder for|
|Route of administration||Intramuscular|
Single pack: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||Protect from Light|
|Life time||2 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 January 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.